首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
【24h】

The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.

机译:血浆可溶性尿激酶纤溶酶原激活物受体(suPAR)水平在III期卵巢癌患者中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

The level of the urokinase plasminogen activator receptor (uPAR) is elevated in tumor tissue from several forms of cancer. uPAR is shed from the cell surface and the soluble form, soluble urokinase plasminogen activator receptor (suPAR), has been detected in several body fluids. High plasma levels of suPAR in patients with colorectal cancer and high serum levels of suPAR in patients with recurrent metastatic breast cancer have been associated with poor prognosis. In patients with ovarian cancer (OC) it has been shown that the level of suPAR is very high in ascites and cystic fluid and that high serum levels of suPAR were associated with shorter survival of the patients. We evaluated suPAR preoperatively in plasma from primary OC stage III patients and tested for association with prognosis. The prognostic significance of suPAR was also compared to two biochemical markers; cancer antigen 125 (CA125) and tetranectin (TN). No significant differences were found between patients who died of OC compared to patients still alive regarding median plasma suPAR levels (p=0.62) and median serum CA125 levels (p=0.26). In contrast, a significant difference was found between dead and alive OC patients for the median serum TN level (p<0.0001). Dividing the patients into two groups, corresponding to preoperative plasma suPAR levels below or equal to 2.0 ng/ml and higher than 2.0 ng/ml, no significant difference in survival was found between the two groups (p=0.49). When different cut-off levels of plasma suPAR were considered (2.74 ng/ml, 3.25 ng/ml and 4.18 ng/ml), no significant differences in survival could be detected (p=0.58, p=0.68 and p=0.05). Multivariate Cox regression analysis showed that the only independent prognostic factors were radicality after primary surgery (RH=5.34; 95% CI, 2.34-12.20; p<0.0001) and preoperative serum TN (RH=0.69, 95% CI, 0.57-0.82; p<0.0001), whereas plasma suPAR (4.18 ng/ml), age, histological type of tumour and serum CA 125 had no independent prognostic value. In conclusion, preoperative plasma suPAR level was of no prognostic value in this cohort of Danish stage III OC patients.
机译:几种形式的癌症在肿瘤组织中尿激酶纤溶酶原激活剂受体(uPAR)的水平升高。 uPAR从细胞表面脱落,在几种体液中已检测到可溶性形式的可溶性尿激酶纤溶酶原激活剂受体(suPAR)。大肠癌患者血浆中suPAR的高水平和复发转移性乳腺癌患者血清中suPAR的高水平与不良预后相关。在患有卵巢癌(OC)的患者中,已显示出腹水和囊性液中suPAR的水平很高,而suPAR的高血清水平与患者的生存期较短有关。我们在术前评估了原发性OC期III期患者血浆中的suPAR,并测试了其与预后的关系。 suPAR的预后意义也与两种生化指标进行了比较。癌抗原125(CA125)和四连蛋白(TN)。死于OC的患者与仍活着的患者之间在血浆suPAR水平中位数(p = 0.62)和血清CA125中位数(p = 0.26)之间无显着差异。相比之下,死者和活着的OC患者之间的血清TN水平中位数存在显着差异(p <0.0001)。将患者分为两组,分别对应于术前血浆suPAR水平低于或等于2.0 ng / ml和高于2.0 ng / ml,两组之间的生存率没有显着差异(p = 0.49)。当考虑血浆suPAR的不同截断水平(2.74 ng / ml,3.25 ng / ml和4.18 ng / ml)时,无法检测到存活率的显着差异(p = 0.58,p = 0.68和p = 0.05)。多因素Cox回归分析显示,唯一的独立预后因素是一次手术后的根治性(RH = 5.34; 95%CI,2.34-12.20; p <0.0001)和术前血清TN(RH = 0.69,95%CI,0.57-0.82;术前血清TN)。 p <0.0001),而血浆suPAR(4.18 ng / ml),年龄,肿瘤的组织学类型和血清CA 125没有独立的预后价值。总之,在该丹麦III期OC患者队列中,术前血浆suPAR水平无预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号